These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26131706)

  • 1. Reverse Cardiac Remodeling: A Marker of Better Prognosis in Heart Failure.
    Reis Filho JR; Cardoso JN; Cardoso CM; Pereira-Barretto AC
    Arq Bras Cardiol; 2015 Jun; 104(6):502-6. PubMed ID: 26131706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implication of cardiac remodeling in heart failure: mechanisms and therapeutic strategies.
    Takano H; Hasegawa H; Nagai T; Komuro I
    Intern Med; 2003 Jun; 42(6):465-9. PubMed ID: 12857042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of ventricular remodeling in heart failure clinical trials.
    Kirkpatrick JN; St John Sutton M
    Curr Heart Fail Rep; 2012 Dec; 9(4):328-36. PubMed ID: 22983907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological modulation of cardiovascular remodeling: a guide to heart failure therapy.
    Remme WJ
    Cardiovasc Drugs Ther; 2003 Jul; 17(4):349-60. PubMed ID: 14618097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 6. Remodeling as an end-point in heart failure therapy.
    Cohn JN
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):7-8. PubMed ID: 15228052
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacologic effects on cardiac remodeling.
    Sharpe N
    Curr Heart Fail Rep; 2004; 1(1):9-13. PubMed ID: 16036019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction.
    Cohn JN; Loscalzo J; Franciosa JA
    J Card Fail; 2003 Oct; 9(5 Suppl Nitric Oxide):S197-8. PubMed ID: 14653276
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathogenesis and pathophysiology of heart failure with reduced ejection fraction: translation to human studies.
    Ge Z; Li A; McNamara J; Dos Remedios C; Lal S
    Heart Fail Rev; 2019 Sep; 24(5):743-758. PubMed ID: 31209771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of angiotensin converting enzyme inhibitors and beta-blockers on left ventricular remodeling after coronary artery bypass graft surgery.
    Maruyama Y; Masaki N; Sato S; Kirimura M; Toyama K; Yuhara M; Sasaki O; Kamiyama T; Nishioka T; Ito H; Yoshimoto N
    Int Heart J; 2008 Jul; 49(4):385-90. PubMed ID: 18753722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?
    Remme WJ
    Cardiol Clin; 2007 Nov; 25(4):581-94; vii. PubMed ID: 18063162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drugs for left ventricular remodeling in heart failure.
    Frigerio M; Roubina E
    Am J Cardiol; 2005 Dec; 96(12A):10L-18L. PubMed ID: 16399088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 18. Regression of left ventricular remodeling in chronic heart failure: Comparative and combined effects of captopril and carvedilol.
    Khattar RS; Senior R; Soman P; van der Does R; Lahiri A
    Am Heart J; 2001 Oct; 142(4):704-13. PubMed ID: 11579363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic and Endovascular Reversal of Left Ventricular Remodeling.
    Jaiswal A; Nguyen VQ; Carry BJ; le Jemtel TH
    J Card Fail; 2016 Oct; 22(10):829-39. PubMed ID: 27109620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Adrenergic activation in heart failure: blockade or rebalance?].
    Emdin M; Vergaro G; Giannoni A; Passino C
    G Ital Cardiol (Rome); 2010 Mar; 11(3):229-32. PubMed ID: 20550063
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.